课题基金 / 基金详情

Molecular and cellular functions of Ano5 in heart

Molecular and cellular functions of Ano5 in heart
Ano5在心脏中的分子和细胞功能
批准号:
8981124
负责人:
Renzhi Han
金额:
$32.82万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-01-01 至 2018-03-31

项目摘要

项目成果

Renzhi Han的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请方提供):质膜完整性对细胞稳态和功能至关重要。质膜的物理、化学或代谢破坏导致细胞中的修复或死亡紧急情况。有效的质膜修复机制对生命至关重要,因为由于基因突变而导致的这一过程的破坏可能导致许多疾病,包括肌营养不良症和相关的心肌病。我们和其他人进行的先前研究表明,包括dysferlin和MG 53在内的几种蛋白质介导了心肌细胞的膜修复反应。然而,这一重要生理过程的分子机制尚未完全确定。我们的初步数据发现,anoctamin 5(Ano5)在肌细胞膜修复中起着重要作用。Ano5属于anoctamin蛋白家族,该家族包括至少十种蛋白质,它们都具有八个跨膜结构域,具有已证实或推定的钙激活氯离子通道(CaCC)功能。ANO5基因(编码ANO5)的突变导致人类患者的肌营养不良症。然而,目前对Ano5在心肌细胞中的分子和细胞功能知之甚少,并且对Ano5介导的膜修复的分子机制仍然知之甚少。这项研究计划的长期目标是了解Ano5在心脏生理和疾病中的分子和细胞机制。在初步研究中,我们发现Ano5主要位于内质网/肌浆网(ER/SR)上,并且Ano5的RNAi沉默显示肌细胞中的膜修复缺陷。这显示了Ano5在肌肉细胞的细胞生理学中的新生物学功能。在这个项目中,我们将专注于测试的假设,即Ano5是参与钙激活的氯离子通道(CaCC)的活动,通过寡聚化的肌浆网(SR),和Ano5起着至关重要的作用,通过促进膜损伤后囊泡的产生,在心肌细胞的质膜修复。我们计划的实验将通过操纵Ano5的表达和使用活细胞成像、生化标记物、离体和体内动物模型研究来显著推进对心肌细胞膜修复机制的理解。这些数据将开始定义用于调节膜修复的潜在治疗靶点,从而治疗与异常膜稳定性相关的疾病。质膜完整性的破坏是许多疾病的基础,包括心肌病。我们的项目旨在了解Ano5在肌肉生理学和疾病中的分子和细胞功能。这些研究将有助于通过调节Ano5介导的膜修复能力来确定治疗与质膜完整性受损相关的心脏病的治疗靶点。
英文摘要
DESCRIPTION (provided by applicant): Plasma membrane integrity is of critical importance for cell homeostasis and function. Physical, chemical or metabolic disruption of the plasma membrane leads to a repair-or-die emergency in the cell. An efficient plasma membrane repair mechanism is essential for life because disruption of this process due to genetic mutations can result in a number of diseases including muscular dystrophy and associated cardiomyopathy. Previous studies conducted by ourselves and others demonstrate that several proteins, including dysferlin and MG53, mediate the membrane repair response in cardiomyocytes. However, the molecular mechanisms underlying this important physiological process has not been fully defined. Our preliminary data found that anoctamin 5 (Ano5) plays an essential role in membrane repair in myocytes. Ano5 belongs to the anoctamin protein family that includes at least ten proteins all possessing eight transmembrane domains with proved or putative calcium-activated chloride channel (CaCC) functions. Mutations in the ANO5 gene (encoding Ano5) lead to muscular dystrophies in human patients. However, there is little known about the molecular and cellular functions of Ano5 in cardiomyocytes and the molecular mechanisms underlying Ano5-mediated membrane repair remain poorly understood. The long-term goal of this research proposal is to understand the molecular and cellular mechanisms for Ano5 in heart physiology and disease. In pilot studies, we found that Ano5 is primarily localized on the endoplasmic/sarcoplasmic reticulum (ER/SR) and RNAi-silencing of Ano5 shows defective membrane repair in myocytes. This shows a new biological function of Ano5 in the cellular physiology of muscle cells. In this project, we will focus on testing the hypothesis that Ano5 is involved in the calcium-activated chloride channel (CaCC) activity through oligomerization on the sarcoplasmic reticulum (SR), and that Ano5 plays an essential role in plasma membrane repair of cardiomyocytes by promoting vesicle generation upon membrane damage. Our planned experiments will significantly advance understanding of cardiomyocyte membrane repair mechanisms by manipulating expression of Ano5 and the use of live cell imaging, biochemical markers, ex vivo and in vivo animal model studies. These data will begin to define potential therapeutic targets for the regulation of membrane repair, thereby treating the diseases associated with abnormal membrane stability. Disrupted plasma membrane integrity underlies a number of diseases including cardiomyopathy. Our project is designed to understand the molecular and cellular functions of Ano5 in muscle physiology and disease. These studies will aid in defining therapeutic targets for the treatment of heart diseases associated with compromised plasma membrane integrity through the regulation of Ano5-mediated membrane repair capacity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Base editing of ASGR1 for cardiovascular disease
Controllable base editing therapy for DMD
ANO5 in Muscle Health and Disease
  • 批准号:
    10378023
  • 项目类别:
  • 资助金额:
    $38.36万
  • 财政年份:
    2019
  • 负责人:
    Renzhi Han
  • 依托单位:
ANO5 in Muscle Health and Disease
国内基金
海外基金
基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
  • 批准号:
    82371144
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    汪雪玲
  • 依托单位:
长寿基因SIRT7调控核苷酸切除修复通路的机制研究
  • 批准号:
    32100605
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    耿安珂
  • 依托单位:
溶酶体蛋白LAPTM4B通过与Xc-系统相互作用调控谷胱甘肽代谢的机制研究
  • 批准号:
    32100623
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    周可成
  • 依托单位:
小鼠肺分支早期发育中肺上皮单细胞的时-空转录组的建立与分析